Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: A cross-sectional study

American Journal of Kidney Diseases

Volumn 63, Issue 4, 2014, Pages 584-589

  Jin, Kyubok ^a   Park, Bong Soo ^a   Kim, Yang Wook ^a   Vaziri, Nosratola D ^b,c  

^a Inje University College of Medicine   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

atherosclerosis; cardiovascular disease; hyperlipidemia; low density lipoprotein (LDL) cholesterol; low density lipoprotein (LDL) receptor; PCSK9 (proprotein convertase subtilisin kexin type 9); Proteinuria

Indexed keywords

ALBUMIN; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SUBTILISIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIET RESTRICTION; END STAGE RENAL DISEASE; ENZYME BLOOD LEVEL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PERITONEAL DIALYSIS; PROTEIN URINE LEVEL; UREA NITROGEN BLOOD LEVEL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; HYPERLIPIDEMIA; LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL; LOW-DENSITY LIPOPROTEIN (LDL) RECEPTOR; PCSK9 (PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9); PROTEINURIA;

ADULT; APOPTOSIS; CHOLESTEROL; CHOLESTEROL, LDL; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PERITONEAL DIALYSIS; PROPROTEIN CONVERTASES; RENAL DIALYSIS; SERINE ENDOPEPTIDASES; YOUNG ADULT;

EID: 84897112851     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.10.042     Document Type: Article

References (27)

1. N.D. Vaziri Molecular mechanisms of lipid dysregulation in nephrotic syndrome (Nephrology Forum) Kidney Int 63 2003 1964 1976
2. J. Joven, C. Villabona, E. Vilella, L. Masana, R. Albertí, and M. Vallés Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome N Engl J Med 323 9 1990 579 584
3. G.L. Warwick, C.J. Packard, and T. Demant et al. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic range proteinuria Kidney Int 40 1991 129 138
4. G.L. Warwick, M.J. Caslake, and J.M. Boulton-Jones et al. Low-density lipoprotein metabolism in the nephrotic syndrome Metabolism 39 1990 187 192
5. N.D. Vaziri, and K. Liang Downregulation of hepatic LDL receptor expression in experimental nephrosis Kidney Int 50 1996 887 893
6. N.D. Vaziri, T. Sato, and K. Liang Molecular mechanism of altered cholesterol metabolism in focal glomerulosclerosis Kidney Int 63 2003 1756 1763
7. N.D. Vaziri, and K. Liang Acyl-CoA cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, LCAT, SRB-1 and LDL receptor deficiencies in nephrotic syndrome Circulation 110 2004 419 425
8. C.H. Kim, H.J. Kim, M. Mitsuhashi, and N.D. Vaziri Hepatic tissue sterol regulatory element binding protein 2 and low-density lipoprotein receptor in nephrotic syndrome Metabolism 56 10 2007 1377 1382
9. L. Wang, G.C. Shearer, M.S. Budamagunta, J.C. Voss, A. Molfino, and G.A. Kaysen Proteinuria decreases tissue lipoprotein receptor levels resulting in altered lipoprotein structure and increasing lipid levels Kidney Int 82 9 2012 990 999
10. K.N. Maxwell, and J.L. Breslow Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype Proc Natl Acad Sci U S A 101 2004 7100 7105
11. T.A. Lagace, D.E. Curtis, and R. Garuti et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice J Clin Invest 116 2006 2995 3005
12. J. Li, C. Tumanut, and J.A. Gavigan et al. Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity Biochem J 406 2007 203 207
13. M.C. McNutt, T.A. Lagace, and J.D. Horton Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells J Biol Chem 282 2007 20799 20803
14. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
15. N.D. Vaziri Dyslipidemia of chronic renal failure: The nature, mechanisms, and potential consequences Am J Physiol Renal Physiol 290 2 2006 F262 F272
16. N.D. Vaziri, and H. Moradi Mechanisms of dyslipidemia of chronic renal failure Hemodial Int 10 1 2006 1 7
17. Liu S, Vaziri ND. Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome [published online ahead of print October 28, 2013]. Nephrol Dial Tranplant. http://dx.doi.org/10.1093/ndt/gft439.
18. W.E. Alborn, G. Cao, and H.E. Careskey et al. Serum proprotein convertase subtilisin kexin type9 is correlated directly with serum LDL cholesterol Clin Chem 53 2007 1814 1819
19. G. Lambert, N. Ancellin, and F. Charlton et al. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment Clin Chem 54 2008 1038 1045
20. D.C. Chan, G. Lambert, P.H. Barrett, K.A. Rye, E.M. Ooi, and G.F. Watts Plasma proprotein convertase subtilisin/kexin type 9: A marker of LDL apolipoprotein B-100 catabolism? Clin Chem 55 2009 2049 2052
21. R. Huijgen, S.M. Boekholdt, and B.J. Arsenault et al. Plasma PCSK9 levels and clinical outcomes in the treating to new targets trial: A nested case-control study J Am Coll Cardiol 59 2012 1778 1784
22. H.J. Jeong, H.S. Lee, K.S. Kim, Y.K. Kim, D. Yoon, and S.W. Park Sterol dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2 J Lipid Res 49 2008 399 409
23. B. Dong, M. Wu, and H. Li et al. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters J Lipid Res 51 2010 1486 1495
24. N.D. Vaziri, and K.H. Liang Upregulation of acyl-coenzyme A: cholesterol acyltransferase (ACAT) in nephrotic syndrome Kidney Int 61 2002 1769 1775
25. P. Costet, B. Cariou, and G. Lambert et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c J Biol Chem 281 2006 6211 6218
26. J.D. Browning, and J.D. Horton Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans J Lipid Res 51 2010 3359 3363
27. L. Persson, G. Cao, and L. Stahle et al. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans Arterioscler Thromb Vasc Biol 30 2010 2666 2672